Ceva Santé Animale has acquired a portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories, from Boehringer Ingelheim following the latter’s acquisition of Merial Animal Health.
All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply.
Ceva has invested heavily in the development of vaccines, as part of its global preventative health strategy, over the past 10 years. Its chairman and CEO Dr Marc Prikazsky said: “We are conscious that we have a responsibility to maintain this strong veterinary scientific tradition. Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow.”
Ceva Santé Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry.
Earlier this month, Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, consisting of an exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business, had been successfully closed in most markets on January 1st 2017. Negotiations for the business swap started in December 2015.